Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A Look into the Future of Chronic Pain Management

An Interview with Innocan Pharma’s CEO, Iris Bincovich. Innocan Pharma is gaining attention for its innovative pain relief solutions — particularly through its slow-release injection technology. This cutting-edge approach delivers synthetic Cannabidi...

NervGen Pharma: Proof that NVG-291 works?

It’s arguably a Eureka moment for investors in NervGen Pharma (TSX.V: NGEN) (OTCQB: NGENF). Tantalizing anecdotal “evidence” has just been published that suggests that NervGen’s prospective wonder-drug — NVG-29...

Buzz on the Bullboards: Feeling holiday blues, or celebrating blue chip stocks?

Are you anticipating a calm market as the holidays approach? Think again. Astute investors and brokers recognize that this is their moment to excel. With the global economy constantly shifting, staying active is the smart move. Over the past week, some shareholde...

Investment expert gives fall stock picks, companies to watch

Brianne Gardner , senior wealth manager at Velocity Investments, Raymond James Canada, recently joined The Market Online to discuss her fall stock picks, companies to watch and her market insights on the financial sector, interest rates and the U.S. election. As y...

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...

Takeover rumours: BioNTech, Cardiol Therapeutics and Novo Nordisk in focus

The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is because of high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany’s economic condit...

Silver price predictions: Is the 2024 gold and silver rally just starting?

By Rob Driscoll Like birds of a feather, gold and silver have historically flocked together, and the two precious metal mates have certainly found their wings in 2024. Gold hit an all-time high in April, and silver parroted the move by breaching the $29 mark l...

Nvidia! Turnaround for Nel, Saturn Oil & Gas, Lufthansa, TUI?

It looks like a peak is forming in artificial intelligence. The most prominent share here is Nvidia (NDAQ:NVDA) . With a spectacular rally, the value has surged by more than 100 per cent in just six months. However, the share price is now stuttering, and there have been ...

A billion-ton copper opportunity in Zambia

The following is a transcription of the above video, and The Market Online has edited it for clarity . Midnight Sun Mining Corp. (TSXV:MMA) is an exploration company focused on its flagship Solwezi Project in the heart of the Zambia-Congo Copper Belt. Here to ...

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
1 2 3 4 5 6 7 8 9 10 ...